Optimizing therapy in treatment-naïve genotype 1 patients
- 21 Downloads
With the current standard dose and duration of pegylated interferon (PEG-IFN) and ribavirin (RBV), a sustained virologic response (SVR) is obtained in about 40% to 45% of patients with hepatitis C virus genotype 1. Few baseline characteristics can be modified to enhance response rates, so the focus of recent studies has been on whether increasing the dose and duration of treatment can improve SVR rates. Emerging data support consideration of higher-dose RBV and possibly higher doses of PEG-IFN. Additionally, for those not achieving a complete early virologic response, extending treatment from 48 to 72 weeks reduces relapse rates and improves sustained responses. Adherence remains an important “on-treatment factor” influencing responses, but studies are inconsistent in terms of what the “critical” cutoff for dose reductions is. At present, the best strategy to maximize SVR rates for genotype 1 and other “difficult-to-treat” populations includes determining whether any baseline factors can be modified before treatment, maximizing adherence, considering use of higher drug doses, and adjusting treatment duration based on early virologic responses.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 36.Rodriguez-Torres M, Sulkowski M, Chung R, et al.: Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with peginterferon alfa-2a/ribavirin. Hepatology 2007, 46:A1305.Google Scholar
- 41.Rodriguez-Torres M, Sulkowski M, Chung RT, et al.: Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with peginterferon alfa-2a/ribavirin [abstract 1305]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar
- 42.Roberts S, Weltman M, Crawford D, et al.: Rapid and early virologic response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study [abstract 54]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar